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Abstract Normal tissue contamination of tumors may eclipse
the detection of loss of heterozygosity (LOH) by microsatellite
analysis and may also hamper isolation of tumor suppressor
genes. To test the potential impact of this problem, we prepared
artificial mixtures of mouse-human microcell hybrid lines that
carried different alleles of the same chromosome 3 marker. After
performing an allele titration assay, we found a consistent
difference between the LOH of a high molecular weight (H)
allele and the LOH of a low molecular weight (L) allele of the
same CA repeat marker. It follows that normal tissue admixtures
will be less of a problem when LOH affects a H allele than with a
L allele. Random screening of 100 papers published between
1994 and 1999 revealed that the loss of a L allele was recorded at
about half the frequency (52%) of loss of a H allele. To avoid this
bias, we have developed rules for the evaluation of LOH data.
We suggest that the loss of a L allele should be given more weight
than the loss of a H allele in LOH studies using microsatellite
markers.
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1. Introduction
Loss of heterozygosity (LOH) is frequently used as an in-
dicator of genetic loss associated with tumor development and
CA repeat analysis using polymorphic microsatellite markers
is often the method of choice for LOH detection. LOH studies
performed on the same chromosomal region of the same type
of tumors have often led to di¡erent results in di¡erent labo-
ratories. Reports di¡er, for example, on the extent of 3p losses
in renal cell carcinoma (RCC) and other solid tumors, with
some papers reporting large terminal deletions and others
claiming interstitial deletions [1,2]. Reports of the frequency
of LOH can also di¡er for the same marker in the same type
of tumor. For instance, D3S1289 was deleted in only 20% of
RCC cases studied by Lubinski et al. [3], but in all the cases
studied by Wilhelm et al. [4]. Foster et al. [5] reported deletion
of marker D3S1317, the VHL gene, in only 20% of cases,
whereas 84% of the cases studied by Shuin et al. [6] showed
deletion of this marker.
The admixture of stroma, blood vessels, lymphocytes and
other normal cells in a tumor is an unavoidable source of
error in LOH studies of solid tumors. If di¡erent markers
are a¡ected to varying degrees by this admixture, spurious
LOH patterns may be obtained. We were alerted to this prob-
lem in a previous study of nasopharyngeal carcinoma (NPH)
[7]. Multiple interstitial deletions were found on the short arm
of chromosome 3 in several tumors, chromosome 3 markers
were lost with frequencies that ranged from 9 to 60% of the
cases. We have referred to this e¡ect as the ‘zebra pattern’.
The question arose whether this pattern is an artifact and
re£ects di¡erences in the sensitivity of detection with di¡erent
markers (where one marker is more a¡ected by normal tissue
contamination than another) or re£ects true cases of intersti-
tial deletions.
In the study of NPC [7], we compared the sensitivity of
detection of three dinucleotide markers (D3S1217, D3S1297
and D3S1304) by PCR. These markers were selected because
they showed di¡erent frequencies of LOH in the study (58%
for D3S1217, 33% for D3S1297 and 9% for D3S1304). After
serially diluting the human DNA with mouse DNA and am-
plifying the DNA using di¡erent primers, no major di¡erences
in sensitivity were detected. The aim of the present study was
to investigate this problem in more detail.
2. Materials and methods
2.1. Cell lines, DNA samples and general methods
DNA was extracted from the mouse-human microcell hybrid
(MCH) lines using the standard phenol extraction method and used
in the allele titration assay (ATA) [8,9]. The cell lines MCH903.1 and
MCH939.2 were used for most of this study. MCH903.1 is a MCH
line that contains a single copy of human chromosome 3, derived
from a normal human diploid cell line (HFDC), as its only human
component [8,10,11]. The MCH939.2 cell line [8,10,11] originally con-
tained a cytogenetically normal chromosome 3 (derived from a nor-
mal human diploid cell line HHW1108), but now carries a small
deletion in the short arm of this chromosome (3p21.3-p22).
Paired normal and tumor RCC tissue samples were obtained im-
mediately after resection and stored at 380‡C before DNA extraction.
Each tumor piece was examined histopathologically and only clear
cell type tumors were used. After DNA extraction, the DNA integrity
was checked by agarose gel electrophoresis.
2.2. Microsatellite analysis
PCR primers were from Nordic Primer Resource (Dept. of Clinical
Genetics, Univ. Hospital, Uppsala, Sweden) and Life Technologies
(Gibco BRL, UK). PCR markers used in the study are assigned (hy-
perlink http://gdbwww.gdb.org/) to 3p26-p25 (D3S1297, D3S1038,
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D3S1317, D3S1304 and D3S1286), to 3p24 (D3S1620, D3S1283), to
3p22 (D3S1611, D3S1298, D3S3527), to 3p21 (D3S1568, D3S2420,
D3S2409, D3S2456, D3S1767, D3S1766, D3S1289), to 3p14
(D3S1285, D3S1217), to 3p13 (D3S2454), to 3p12 (D3S2406), to
3q13 (D3S1278), to 3q21-3q25 (D3S47), to 3q27 (D3S1265) and to
3q28 (D3S1314 and SST).
PCR was performed in a 15 Wl reaction volume, containing 2.5^5.0
pmol of each primer, 0.2 mM of each dNTP, 50^200 ng template
DNA and 1 U Taq DNA polymerase. One of the paired primers
(0.25 pmol) in the reaction mixture was end-labelled with [Q-32P]ATP
using T4 polynucleotide kinase. The DNA samples were ampli¢ed by
30 PCR cycles comprising 1 min denaturation at 94‡C, 1 min at the
appropriate annealing temperature and 1 min at 72‡C, in a Techne
PHC-3 thermal cycler and Perkin Elmer GeneAmp PCR System 2400
(Foster City, CA, USA).
According to the size of microsatellite marker, electrophoresis was
carried out in a 4.5^6.5% acrylamide/7 M urea gel at 60‡C at a con-
stant power of 60 W. After electrophoresis, the gels were exposed to
X-ray ¢lm at 380‡C (Fuji, Tokyo, Japan). Densitometry was then
performed using a Molecular Dynamics Personal Densitometer SI
(Sunnyvale, CA, USA) according to the manufacturer’s protocol.
3. Results and discussion
3.1. ATA studies
Using the ¢ve available MCH lines that contained chromo-
some 3 from di¡erent patients [8,9], we performed an ATA
using DNA samples mixed in a ratio that mimicked the mixed
cell population found in tumor biopsies. DNA from two
MCH lines that carry di¡erent alleles at speci¢c loci was
mixed in di¡erent proportions and then analyzed by PCR
using six microsatellite markers (D3S1217, D3S1283,
D3S1289, D3S1297, D3S1304 and D3S1317) distributed along
the short arm of chromosome 3. Some of these markers were
also used in our previous study [7].
All markers gave very similar titration curves in the ATAs
(e.g. D3S1304 and D3S1217, Fig. 1). This is consistent with
our conclusion from our previous study [7] that di¡erent
markers are detected with similar sensitivities. However, anal-
ysis of the data indicated an unexpected systematic di¡erence
between the titration curves of the high and low molecular
weight (H and L) alleles of the same marker (Fig. 1). A de-
crease of the H allele signal could be detected if the frequency
of the ‘contaminating normal cells’ was less than 80% (60% or
more of the L allele). In contrast, loss of the L allele could
only be detected if the frequency of the ‘contaminants’ was
less than 60% (70% or more of the H allele).
All the assayed markers showed a similar allele detection
asymmetry, although to various degrees. The reasons for this
asymmetry may be related to the non-linearity of the radio-
autographic signal on X-ray ¢lms (as described in the Amer-
sham Catalogue), although a number of other factors may
contribute to this phenomenon, for example, the stronger sig-
nal of the L allele compared with the H allele. Using DNA
isolated from three healthy individuals, we measured the ratio
between the L and H alleles of eight random CA repeat
markers (D3S1265, D3S47, SST, D3S1278, D3S1314,
D3S1297, D3S1611 and D3S1620). In all cases, the ratio of
these alleles was higher than 1, with an overall average ratio
of 1.73. This is surprising: usually, sequences ampli¢ed with
the same PCR primers producing products with minimal dif-
ferences in length (e.g. 250 and 254 bp) would not be expected
to exhibit di¡erent PCR ampli¢cation rates. Conceivably, Taq
polymerase may not discriminate between ampli¢cation prod-
ucts of 250 and 254 bp, but may discriminate between (CA)n
and (CA)n2 repeats. This may be related to the ‘slippage’ of
Taq polymerase (as well as other DNA polymerases) when it
ampli¢es stretches of simple nucleotide repeats. It has also
been noted that simple repeats can cause replication blockage
in vivo [12]. Stronger signals for the L allele have also been
mentioned earlier [13,14].
The existence of shadow bands (generated when Taq poly-
merase slips over short tandem repeats thus producing shorter
products) may be another factor a¡ecting the asymmetry of
allele detection. Shadow bands from a H allele may increase
the strength of a L allele. We measured the signal intensity of
H and L bands of all the markers tested in this study, using a
Molecular Dynamics Personal Densitometer SI. For the dilu-
tions in which the proportion of H allele was 10^50%, the
ratio of signal intensity (HR = H/L) between H and L was
calculated for ¢ve points (1 = 10% of H and 90% of L allele,
2 = 20% of H and 80% of L, etc.). For the DNA ratios where
the L allele represented 10^50% of the mixed DNA sample,
the ratio of signal intensity between the L allele and the H
allele (LR = L/H) was given a similar point score (1 = 10% of
L allele, etc.). The ratio between LR and HR was calculated
for each of the ¢ve points, for all markers.
Fig. 1. Microsatellite analysis of six CA-polymorphic markers.
DNAs for ATA were obtained from MCH lines [8^11]. Lanes 1^9
contain from 10 to 90% of DNA with H allele, respectively. The
upper part of the ¢gure shows correlation between the content of H
and L alleles and ‘tumor/normal DNA’. The loss for allele H could
be unambiguously detected up to 60% of normal cell admixture, but
not at 80% or more. In contrast, loss of the L allele could only be
detected if the normal cell admixture was less than 40%. It could
not be observed at 60% or more. This bias implies that normal cell
admixture obscures the detectability of LOH from tumor cells to a
di¡erent extent, depending on whether the loss a¡ects the L or the
H allele of the same locus.
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The ratio of LR to HR was maximal when the mixed DNA
sample contained 20^30% of either of the two alleles (Fig. 1,
lanes 2 and 3 compared with lanes 7 and 8). This range de-
¢ned the zone of highest sensitivity for the detection of H
allele loss compared with L allele loss, suggesting that in
samples that contain 40^60% normal cells, H allele loss may
be detected, but L allele loss may be missed. Normal cell
admixtures, therefore, may obscure the detection of LOH in
tumors to a varying extent, depending on whether the loss
a¡ects the L or the H allele of the same locus. In Fig. 2,
the data from the mixed DNA samples are presented with
the theoretical curves for allele deletion in the presence of
varying proportions of H and L alleles. For example, 10%
of one allele in the mixed DNA sample corresponded to
20% normal cell DNA contamination of the tumor sample,
20% of either L or H alleles in the DNA mixture corre-
sponded to 40% normal cell contamination, etc.
Fig. 2 shows the di¡erences between detection of the H and
L alleles at the same normal DNA contamination levels. Loss
of the H allele could be unambiguously detected in the mixed
DNA samples containing up to 60% of normal cell DNA, but
H allele loss could not be detected when the normal cell DNA
represented 80% or more of the sample. In contrast, loss of
the L allele could only be detected when the normal cell ad-
mixture represented 40% or less of the sample. L allele loss
could not be observed when the normal cell admixture formed
60% or more of the DNA sample.
Fig. 2 indicates a series of zones. The ¢rst zone represents
the informative region of the curve, where LOH can be clearly
detected. A non-informative zone, where LOH cannot be de-
tected, and a risk zone, where detection of LOH is ambiguous,
are also apparent. In LOH analysis of real tumor samples, it is
not known whether the H or the L allele of a given marker is
deleted. As tumors may carry 20^60% admixed normal cells,
many cases will be in the risk zone. The upper limit of the risk
zone for the L allele is usually 40%, but in some cases may be
as low as 20%. In these cases, the risk zone may be signi¢-
cantly greater. This implies that unambiguous LOH data can
only be obtained from samples containing less than 20% con-
taminating material and the probability of detecting a LOH in
the presence of contaminating normal cells is higher with re-
gard to the H allele compared with the L allele.
3.2. Di¡erence in detection of allele losses and three rules for
LOH analysis
If the bias described in this study has in£uenced the LOH
studies of solid tumors, we would expect that losses of the H
allele were more frequently detected than losses of the L allele.
We have checked 100 randomly selected papers published
between 1994 and 1999 that included LOH studies. Table 1
shows the reported loss of the H allele versus the L allele.
Altogether, the studies report 530 cases with deletion of the
H allele and 275 cases with L allele deletions. Statistical anal-
ysis of these results based on z approximation (z = 8.95) of a
binominal test (two-tailed PI0.00001) showed that the ob-
served di¡erence in detection of allele loss is highly signi¢cant.
For comparison, at z = 4, P is less than 0.00003. These results
suggest that about 50% of the L allele deletions in tumor
samples may go undetected.
Our preliminary data suggest that the conclusions drawn
for dinucleotide markers also apply to trinucleotide and tet-
ranucleotide markers. We analyzed our recently published
data of deletion mapping of 3p in di¡erent epithelial tumors
[115] using trinucleotide and tetranucleotide markers for a
total of seven loci. We found that, in epithelial tumors, L
allele deletions were also detected less frequently than H allele
deletions (99 of L allele loss versus 142 of H allele, z = 2.7,
P = 0.0035). Although this study of epithelial tumors was not
Fig. 2. Summary data from the dilution experiments. They are shown together with theoretical curves representing the deletion of one allele at
di¡erent proportions of H and L alleles. For example, 10% of one allele in our dilution experiments corresponds to 20% of contamination of
tumor with normal cell DNA. The ¢gure shows the di¡erences between H and L allele detection at the same level of normal DNA contamina-
tion and indicates the informative zone where LOH is clearly detectable, a non-informative zone where it cannot be detected, and a risk zone
where its detectability is ambiguous.
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very extensive, we think that the di¡erence in H and L allele
detection we observed is important because the tumor samples
were puri¢ed by microdissection and the L to H allele ratio
for the CA repeat markers was 58:72 (z = 1.14, P = 0.1217).
On the basis of this study, we suggest to follow three rules
for LOH analysis :
1. Comparative genome hybridization [116] or other inde-
pendent methods (quantitative PCR, Southern hybridiza-
tion) must be used in parallel with microsatellite analysis to
exclude false ‘interstitial’ deletions.
2. The number of deleted H and L alleles should be counted
for each paired sample of normal and tumor tissue. These
numbers should be about the same.
3. Most importantly, the rule for the L allele must be taken
into consideration during LOH analysis. This means that
the retention of markers should be evaluated with caution,
particularly if they are associated with interstitial deletions
(zebra pattern). Only retained markers located in the neigh-
borhood of the LOH involving a L allele should be eval-
uated as signi¢cant. Otherwise, if no independent suppor-
tive data are available, the retained marker should be
considered non-informative.
As an example of how these rules can in£uence the results
of LOH experiments, data from the RCC analysis presented
in Fig. 3A have been re-interpreted and are shown in Fig. 3B.
All tumor cases (T1^T4) showed deleted, non-informative and
retained alleles (Fig. 3A,C). We concluded that T1, T2 and T3
had a single interstitial deletion in each sample and T4 con-
tained two interstitial deletions (Fig. 3A). However, when we
Table 1
Frequencies of losses of H versus L alleles
Study no. Number of
H allele losses
Number of
L allele losses
Reference
1 4 2 [15]
2 1 3 [16]
3 8 5 [17]
4 4 1 [18]
5 3 2 [19]
6 6 6 [20]
7 6 3 [21]
8 6 3 [22]
9 5 4 [23]
10 6 2 [24]
11 2 2 [25]
12 5 3 [26]
13 5 3 [27]
14 3 2 [28]
15 4 1 [29]
16 6 2 [30]
17 5 1 [31]
18 15 7 [32]
19 2 2 [33]
20 3 1 [34]
21 1 3 [35]
22 11 1 [36]
23 5 5 [37]
24 4 6 [38]
25 5 4 [39]
26 11 8 [40]
27 3 0 [41]
28 6 5 [42]
29 6 2 [43]
30 1 3 [44]
31 5 2 [45]
32 5 3 [46]
33 11 7 [47]
34 16 8 [48]
35 3 1 [49]
36 5 1 [50]
37 4 1 [51]
38 5 1 [52]
39 4 0 [53]
40 3 2 [54]
41 6 4 [55]
42 4 3 [56]
43 4 2 [57]
44 3 3 [58]
45 3 1 [59]
46 6 3 [60]
47 6 4 [61]
48 7 3 [62]
49 8 6 [63]
50 10 5 [64]
51 2 5 [65]
52 4 3 [66]
53 7 3 [67]
54 2 3 [68]
55 11 4 [69]
56 4 2 [70]
57 4 2 [71]
58 4 0 [72]
59 1 5 [73]
60 4 1 [74]
61 7 1 [75]
62 3 2 [76]
63 3 2 [77]
64 4 2 [78]
65 3 1 [79]
66 4 4 [80]
67 13 5 [81]
68 4 1 [82]
69 5 1 [83]
70 2 3 [84]
71 13 2 [85]
Table 1 (continued)
Frequencies of losses of H versus L alleles
Study no. Number of
H allele losses
Number of
L allele losses
Reference
72 8 2 [86]
73 12 7 [87]
74 2 2 [88]
75 5 5 [89]
76 3 1 [90]
77 2 2 [91]
78 10 6 [92]
79 4 2 [93]
80 3 2 [94]
81 4 3 [95]
82 6 1 [96]
83 12 5 [97]
84 8 0 [98]
85 10 2 [99]
86 2 0 [100]
87 11 7 [101]
88 6 4 [102]
89 3 1 [103]
90 4 1 [104]
91 9 6 [105]
92 2 1 [106]
93 3 0 [107]
94 8 1 [108]
95 1 2 [109]
96 5 5 [110]
97 4 1 [111]
98 2 0 [112]
99 4 2 [113]
100 3 0 [114]
Total 530 275
275:530 = 0.52
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Fig. 3. Microsatellite analysis of RCC biopsies. A: Results of LOH analysis. B: Evaluation of LOH data using the ATA rules. C: Representa-
tive examples of autoradiograms demonstrating retention and LOH in RCC samples. A deleted allele is designated by an arrow; NI, non-infor-
mative.
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calculated the number of H and L allele deletions, we found
that for T1, the ratio was 2:5, for T2 6:5 and for T3 and T4
6:0 and 5:0, respectively. The L allele deletion (D3S2420) in
T1 is close to the retained allele D3S1568 and the L allele
deletion (D3S1298) in T2 is close to the retained allele
D3S3527, suggesting that the interstitial deletions in these
cases are genuine. At the same time, L allele deletions were
not detected in T3 and T4. This suggests that these samples
might have terminal deletions (Fig. 3B). To demonstrate the
presence of the interstitial deletions in T3 and T4, other meth-
ods are required, such as comparative genome hybridization
or quantitative PCR or ATA analysis using more microsatel-
lite markers.
Although the rules suggested for LOH analysis in this study
decrease the informativeness of microsatellite analysis, they
sharply increase the con¢dence in informative results and
help to re-evaluate the con£icting data that have been gener-
ated from a number of laboratories.
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